Cigna Common Denials-why Claims Get Rejected
- 01. Cigna prior auth: the top reasons people get denied
- 02. Why Cigna prior auth denials matter
- 03. Top 5 reasons for Cigna prior auth denials Not medically necessary: Cigna's clinical algorithms or medical directors often flag a procedure as "not medically necessary" if the submitted diagnosis code, prior treatment history, or symptom documentation does not map tightly to the insurer's internal coverage policy. This category is the single largest bucket, generating about 35-40% of all prior auth denials in 2024-2025 according to provider revenue-cycle data. Step therapy not met: Many plans require patients to try and fail cheaper, generic, or first-line therapies before approving higher-cost drugs; if the request omits dates, doses, or clear reasons for discontinuation, Cigna typically denies it outright. For example, in a 2025 analysis of rheumatology authorizations, 28% of biologic denials were tied to incomplete step-therapy documentation. Experimental or investigational: Cigna classifies some therapies-especially certain off-label biologics or advanced genetic tests-as "experimental" if there is insufficient evidence in its coverage policy, even when peer-reviewed guidelines support them. This label can be applied pre-emptively via automated systems such as PXDX, which cross-checks CPT and ICD-10 codes against internal pathways. Duplicate or frequency-limited service: If Cigna's system flags a new procedure or infusion as a duplicate service or "too frequent" based on prior claims, it may auto-deny without a deep chart review. This is common with imaging, physical therapy, and recurring infusions, where re-authorization windows are strict. Missing or mismatched documentation: Up to 20% of denials trace to missing lab values, prior denials, CPT codes, or a mismatch between the authorization and the billed service. When a claim is submitted without the required precertification, Cigna will routinely reject it with CO-45 ("not covered") and then expect an appeal with retroactive authorization. Sample denial patterns in tabular form
- 04. How Cigna's internal systems shape denials
- 05. Which services are most often denied
- 06. When and how to appeal a Cigna denial
- 07. Key takeaways for members and providers
Cigna prior auth: the top reasons people get denied
Most patients get their Cigna prior authorization denied for one of five reasons: the service is deemed "not medically necessary," step therapy rules aren't met, the treatment is labeled "experimental or investigational," there's a perceived duplicate or too-frequent service, or the request lacks proper documentation or coding. These patterns repeat across commercial, Medicare Advantage, and employer plans, and they account for roughly 70-80% of all Cigna precertification denials in recent internal provider analyses.
Why Cigna prior auth denials matter
For patients, a denied prior authorization can delay or block surgery, imaging, infusion therapy, or specialty medications, even when a clinician has signed off. For providers, these denials convert into claim rejections such as CO-16 ("not medically necessary") or CO-45 ("not covered: no authorization"), which shrink revenue and increase administrative burnout. In 2023, Cigna rolled back prior authorization on about 600 diagnostic and surgical codes, yet members still experience roughly 15-20% denial rates on remaining high-cost services according to provider-side audits.
Top 5 reasons for Cigna prior auth denials
- Not medically necessary: Cigna's clinical algorithms or medical directors often flag a procedure as "not medically necessary" if the submitted diagnosis code, prior treatment history, or symptom documentation does not map tightly to the insurer's internal coverage policy. This category is the single largest bucket, generating about 35-40% of all prior auth denials in 2024-2025 according to provider revenue-cycle data.
- Step therapy not met: Many plans require patients to try and fail cheaper, generic, or first-line therapies before approving higher-cost drugs; if the request omits dates, doses, or clear reasons for discontinuation, Cigna typically denies it outright. For example, in a 2025 analysis of rheumatology authorizations, 28% of biologic denials were tied to incomplete step-therapy documentation.
- Experimental or investigational: Cigna classifies some therapies-especially certain off-label biologics or advanced genetic tests-as "experimental" if there is insufficient evidence in its coverage policy, even when peer-reviewed guidelines support them. This label can be applied pre-emptively via automated systems such as PXDX, which cross-checks CPT and ICD-10 codes against internal pathways.
- Duplicate or frequency-limited service: If Cigna's system flags a new procedure or infusion as a duplicate service or "too frequent" based on prior claims, it may auto-deny without a deep chart review. This is common with imaging, physical therapy, and recurring infusions, where re-authorization windows are strict.
- Missing or mismatched documentation: Up to 20% of denials trace to missing lab values, prior denials, CPT codes, or a mismatch between the authorization and the billed service. When a claim is submitted without the required precertification, Cigna will routinely reject it with CO-45 ("not covered") and then expect an appeal with retroactive authorization.
Sample denial patterns in tabular form
| Denial category | Common CARC/code | Approximate share of Cigna denials (2024-2025) | Quick fix at the provider level |
|---|---|---|---|
| Not medically necessary | CO-16, CO-96 | 35-40% | Attach diagnosis details, prior treatment history, and guideline citations to every prior auth. |
| No prior auth obtained | CO-45, CO-197 | 20-25% | Always submit precertification before service date and reference auth number on claim. |
| Step therapy / formulary issue | Drug-specific internal codes | 15-20% | List all prior agents, dates, doses, and specific adverse events or lack of response. |
| Duplicate / frequency-limited | CO-50, system flags | 10-15% | Clarify medical need, document change in condition, and request re-evaluate for medical necessity. |
| Incorrect or incomplete coding | CO-50, CO-197 | 10-15% | Match CPT/ICD-10 across auth, orders, and claims; avoid unbundling. |
Data in this table are synthesized from 2024-2025 provider revenue-cycle audits and insurer documentation, and are not official Cigna statistics.
How Cigna's internal systems shape denials
Cigna relies on an automated engine called PXDX that cross-checks diagnosis-procedure pairs against predetermined coverage policy pathways, often flagging mismatches in seconds. ProPublica and other watchdogs have reported that some Cigna medical directors review prior authorization decisions at a pace of hundreds per day, with some cases receiving less than two minutes or even 1.2 seconds of human attention. When machine-driven rules classify a service as "not medically necessary" or "experimental," the physician may never see a detailed clinical justification, which complicates appeals.
Which services are most often denied
- High-cost specialty drugs such as biologics and oncology agents frequently run into step-therapy or "not medically necessary" denials, especially when prior agents are under-documented.
- Advanced imaging like repeated MRIs or CT scans, particularly without clear change in clinical status or justification, are often flagged for frequency or duplication.
- Invasive procedures and surgeries that require precertification (for example, certain orthopedic or spine operations) are vulnerable to CO-45 or CO-16 if the prior auth is missing or inadequately supported.
- Genetic and molecular testing used outside tight guideline indications may be categorized as "experimental" until the request aligns closely with the payer's policy language.
- Durable medical equipment (DME) from 2020-2025 saw a big reduction in prior authorization requirements, but remaining DME codes still face medical-necessity hurdles.
When and how to appeal a Cigna denial
Cigna's official processes allow both members and providers to appeal prior authorization decisions internally, usually within 180 days of the denial letter, and then escalate to external review if the internal appeal fails. Successful appeals often include a direct line-by-line comparison of the payer's stated coverage criteria with the clinical facts in the chart, plus dosing histories, lab trends, and guideline citations. For example, a 2025 study of rheumatology appeals showed that well-structured responses listing every prior therapy with dates, doses, and specific reasons for discontinuation reversed 60-70% of step-therapy denials on first appeal.
Key takeaways for members and providers
Understanding the top Cigna prior authorization denial patterns helps members anticipate delays and supports providers in crafting bullet-proof first-pass requests. By focusing on tight alignment with coverage policies, thorough step-therapy histories, and precise coding, both clinicians and patients can significantly improve approval odds and reduce appeal workload.
Expert answers to Cigna Common Denials Why Claims Get Rejected queries
What is the most common reason for Cigna prior authorization denials?
The most common reason for Cigna prior authorization denials is that the service is deemed "not medically necessary," followed closely by denials tied to missing or incomplete prior authorization. In practice, this means the insurer's coverage policy or algorithm does not see enough documented evidence that the requested care meets the defined clinical criteria for that diagnosis.
Can step therapy denials be overturned?
Yes, many step therapy denials can be overturned by submitting a detailed history of prior agents, including start and stop dates, daily doses, and specific reasons for discontinuation (for example, liver enzyme elevations, infection, or inadequate response). Appeals that explicitly map each prior drug to the criteria in Cigna's coverage policy and reference major society guidelines (such as ACR or NCCN) tend to have higher reversal rates.
Should providers request prior authorization before every high-cost service?
Yes, providers should request prior authorization before any service that Cigna's policy lists as requiring precertification, because performing a procedure without it typically triggers a CO-45 or similar denial. Even if the portal suggests the service is "likely covered," coverage is never guaranteed and Cigna may still deny the claim if the authorization is missing or mismatches the billed service.
How long does Cigna take to review prior authorization appeals?
Cigna generally responds to prior authorization appeals within about 14-30 days depending on the urgency of the service and whether an expedited review is requested. For time-sensitive or life-threatening conditions, providers can request an expedited review, which may compress the timeline to 72 hours or less, but the exact window can vary by plan and state mandate.
Are there any Cigna services that no longer require prior authorization?
Yes; since 2020, Cigna has removed prior authorization from more than 1,100 codes, including many surgical, genetic testing, and durable medical equipment codes, so those services now bypass precertification. This change follows provider pressure and regulatory scrutiny, and it has reduced the overall volume of prior auth denials, though the remaining high-cost codes remain heavily scrutinized.
How can practices reduce Cigna prior authorization denials?
Practices can reduce prior authorization denials by standardizing documentation templates that always include diagnosis codes, prior therapies with dates and reasons for discontinuation, and relevant lab values or imaging reports. Integrating these data into the authorization request and verifying that CPT and ICD-10 codes match exactly between the authorization and the final claim can cut preventable denials by 30-50% according to provider-side case studies.